Eplerenone in patients with systolic heart failure and mild symptoms

Cited by (1,005)

Items 601–700 of 1,005

1. Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys
   Rainer E. Martin, Johannes D. Aebi, Benoit Hornsperger, Hans-Jakob Krebs, Bernd Kuhn, A. Kuglstatter, André Alker, Hans Peter Märki, Stephan G. Müller, Dominique Burger et al. · 2015 · Journal of Medicinal Chemistry
2. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study
   Hiroyuki Tsutsui, Shin‐ichi Momomura, Yoshihiko Saito, Hiroshi Ito, Kazuhiro Yamamoto, Tomomi Ohishi, Naoko Okino, Weinong Guo · 2016 · Journal of Cardiology
3. The Mortality Risk of Deferring Optimal Medical Therapy in Heart Failure: A Systematic Comparison Against Norms for Surgical Consent and Patient Information Leaflets
   Sameer Uz Zaman, Saman Zaman, Timothy Scholtes, Matthew James Shun-Shin, Carla M. Plymen, Dárrel P. Francis, Graham D. Cole · 2017 · European Journal of Heart Failure
4. Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction
   Miguel Pinilla-Vera, Virginia Shalkey Hahn, David A. Kass · 2019 · Circulation Research
5. 2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure.
   Chun Chieh Wang, Cho‐Kai Wu, Ming‐Lung Tsai, Chi‐Ming Lee, Wei Chun Huang, Hsin‐Hua Chou, Jin Long Huang, Nai‐Hsin Chi, Hsueh‐Wei Yen, Bing‐Hsiean Tzeng et al. · 2019 · PubMed Central
6. Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study
   Julie Rouette, Emily Gibson McDonald, Tibor Schuster, James M. Brophy, Laurent Azoulay · 2022 · BMJ Open
7. Treatment of type 2 diabetes patients with heart conditions
   Gülali Aktaş, Burçin Meryem Atak Tel, Mustafa Ramiz Tel, Buse Balci · 2023 · Expert Review of Endocrinology & Metabolism
8. Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee
   Monica M Colvin, Nancy K. Sweitzer, Nancy M. Albert, Rajan Krishnamani, Michael W. Rich, Wendy Gattis Stough, Mary Norine Walsh, Cheryl A. Westlake Canary, Larry A. Allen, Mark R. Bonnell et al. · 2015 · Journal of Cardiac Failure
9. Incremental Cost-Effectiveness of Guideline-Directed Medical Therapies for Heart Failure
   Gaurav Banka, Paul A. Heidenreich, Gregg C. Fonarow · 2013 · Journal of the American College of Cardiology
10. Apocynin attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction in mice
    Yuqiong Li, Xiaobo Li, Shujie Guo, Shaoli Chu, Pingjin Gao, Dingliang Zhu, Wenquan Niu, Nan Jia · 2013 · Acta Pharmacologica Sinica
11. Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease
    Amy McCurley, Adam P. McGraw, Dafina Pruthi, Iris Zamir Jaffe · 2013 · Pflügers Archiv - European Journal of Physiology
12. Aldosterone and Left Ventricular Remodeling
    GianLuca Colussi, Gabriele Brosolo, Marileda Novello, Leonardo Alberto Sechi, Cristiana Catena · 2015 · Hormone and Metabolic Research
13. Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men’s Issue?
    Antonis S. Manolis, Theodora A. Manolis, Helen Melita, Antonis S. Manolis · 2019 · Current Hypertension Reports
14. Low Skeletal Muscle Mass Independently Predicts Mortality in Patients with Chronic Heart Failure after an Acute Hospitalization
    Persio David Lopez, Pankaj Nepal, Adedoyin A Akinlonu, Divya K. Nekkalapudi, Kwon Kim, Eder H. Cativo, Ferdinand Visco, Savi Mushiyev, Gerald Pekler · 2019 · Cardiology
15. The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease
    M. Elizabeth Moss, Brigett V. Carvajal, Iris Zamir Jaffe · 2019 · Pharmacology & Therapeutics
16. Neprilysin Inhibition — A Novel Therapy for Heart Failure
    Mariell L Jessup · 2014 · New England Journal of Medicine
17. Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?
    Francisco Leyva, Carsten Walter Israel, Jagmeet P. Singh · 2023 · Circulation
18. Heart Failure in Patients with Chronic Kidney Disease
    Andrew V. Xanthopoulos, Adamantia Papamichail, Αlexandros Briasoulis, Konstantinos Loritis, Angeliki Bourazana, Dimitrios E. Magouliotis, Pantelis A. Sarafidis, Ioannis Stefanidis, John S. Skoularigis, Filippos K. Triposkiadis · 2023 · Journal of Clinical Medicine
19. Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians
    Lingling Wu, Mario Rodríguez, Karim El Hachem, Chayakrit Krittanawong · 2024 · Journal of Clinical Medicine
20. JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
    Takeshi Kitai, Shun Kohsaka, Takao Kato, Eri Toda Kato, Kimi Sato, KANAKO TERAMOTO, Hidenori Yaku, Eiichi Akiyama, Masahiko Ando, Chisato Izumi et al. · 2025 · Journal of Cardiac Failure
21. Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases
    Francesco Fioretti, Jeffrey Moore Testani, Maria Clarissa Tio, Bertram Pitt, Javed Butler · 2025 · Journal of the American College of Cardiology
22. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias
    Christian Jøns, Chaoqun Zheng, Ulrik Winsløw, Elisabeth M. Danielsen, Tharsika Sakthivel, Emil A. Frandsen, Hillah Saffi, Sadjedeh S. Vakilzadeh-Hashemi, Ketil Haugan, Niels Eske Bruun et al. · 2025 · New England Journal of Medicine
23. A Randomized Pilot Study of Aortic Waveform Guided Therapy in Chronic Heart Failure
    Barry A. Borlaug, Thomas Patrick Olson, Sahar Abdelmoneim Mohamed, Vojtěch Melenovský, Vincent L. Sorrell, Kelly Noonan, Grace Lin, Margaret M. Redfield · 2014 · Journal of the American Heart Association
24. Treatment of Heart Failure with Preserved Ejection Fraction
    Adriana Mihaela Ilieșiu, Andreea Simona Hodorogea · 2018 · Advances in experimental medicine and biology
25. The role of the kidney in acute and chronic heart failure
    Gaetano M. Ruocco, Alberto Palazzuoli, Jozine M. ter Maaten · 2019 · Heart Failure Reviews
26. MiRNA-181a is a Novel Regulator of Aldosterone–Mineralocorticoid Receptor-Mediated Cardiac Remodelling
    Ankita Garg, Ariana Foinquinos, Mira Jung, Heike Janssen‐Peters, Sinje Biß, Johann K Bauersachs, Shashi Kumar Gupta, Thomas Thum · 2020 · European Journal of Heart Failure
27. Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms
    Johann K Bauersachs, Achim Lother · 2022 · Kidney International Supplements
28. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: Systematic review and meta-analysis
    Francesco Pelliccia, Giuseppe Patti, Giuseppe M.C. Rosano, Cesare Greco, Carlo Gaudio · 2014 · International Journal of Cardiology
29. The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines
    Abdallah Al‐Mohammad, Jonathan Mant · 2011 · Heart
30. Association of Spironolactone Use With All-Cause Mortality in Heart Failure
    Lars H. Lund, Bodil Svennblad, Håkan Melhus, Pär Hallberg, Ulf Dahlström, Magnus Edner · 2013 · Circulation Heart Failure
31. Treatment of Heart Failure With Preserved Ejection Fraction
    Marc Alan Pfeffer, Eugene Braunwald M. D · 2016 · JAMA Cardiology
32. Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension
    Shigeru Shibata, Kenichi Ishizawa, Shunya Uchida · 2016 · Hypertension Research
33. Kyoto Congestive Heart Failure (KCHF) Study: Rationale and Design
    Erika Yamamoto, Takao Kato, Neiko Ozasa, Hidenori Yaku, Yasutaka Inuzuka, Yodo Tamaki, Takeshi Kitai, Takeshi Morimoto, Ryoji Taniguchi, Moritake Iguchi et al. · 2017 · ESC Heart Failure
34. Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure
    Wouter Ouwerkerk, Aeilko Having Zwinderman, Leong L. Ng, Biniyam G. Demissei, Hans L. Hillege, Faiez M. Zannad, Dirk Jan van Veldhuisen, Nilesh J. Samani, Piotr P. Ponikowski, Marco Metra et al. · 2018 · Journal of the American College of Cardiology
35. Heart failure management in dialysis patients: Many treatment options with no clear evidence
    Bethany Angela Roehm, Gaurav Gulati, Daniel E. Weiner · 2020 · Seminars in Dialysis
36. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial
    Jawad H. Butt, José Carlos Nicolau, Subodh Verma, Kieran F. Docherty, Mark Colquhoun Petrie, Silvio E. Inzucchi, Morten Schou, Mikhail Kosiborod, Anna Maria Langkilde, Felipe A. Martínez et al. · 2021 · European Journal of Heart Failure
37. The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
    John J.V. McMurray, Scott David Solomon, Kieran F. Docherty, Pardeep S. Jhund · 2019 · European Heart Journal
38. Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease
    Masatake Kobayashi, Bertram Pitt, João Pedro Ferreira, Patrick Rossignol, Nicolas Girerd, Faiez M. Zannad · 2025 · European Heart Journal
39. Treatment of Severe Metabolic Alkalosis in a Patient With Congestive Heart Failure
    Aldo J. Peixoto, Robert J. Alpern · 2013 · American Journal of Kidney Diseases
40. Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic Dysfunction
    Srinivas R. Bapoje, Amit Bahia, John E. Hokanson, Pamela N. Peterson, Paul A. Heidenreich, JoAnn M. Lindenfeld, Larry A. Allen, Frederick A. Masoudi · 2013 · Circulation Heart Failure
41. Health Reform
    OECD · 2011 · OECD eBooks
42. Arrhythmogenic Remodeling in the Failing Heart
    Zoltán Husti, András Varró, István Baczkó · 2021 · Cells
43. Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)
    Pantelis A. Sarafidis, Fotini Iatridi, Charles Joseph Ferro, Maria Eleni Alexandrou, Beatriz Fernández‐Fernández, Mehmet Kanbay, Francesca Mallamaci, Ionuţ Nistor, Patrick Rossignol, Christoph Wanner et al. · 2023 · Clinical Kidney Journal
44. Impact of Worsening Renal Function Related to Medication in Heart Failure
    Hans‐Peter Brunner‐La Rocca, Christian Knackstedt, Luc W.M. Eurlings, Vinzent Rolny, Friedemann Krause, Matthias Emil Pfisterer, Daniel Tobler, Peter R. Rickenbacher, Micha Tobias Maeder, for the TIME-CHF investigators · 2014 · European Journal of Heart Failure
45. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy
    Sara S. Roscioni, Dick de Zeeuw, Stephan J. L. Bakker, Hiddo J.L. Heerspink · 2012 · Nature Reviews Nephrology
46. Potassium Balance in Dialysis Patients
    Sarah F. Sanghavi, Susan Joyce Whiting, Jaime Uribarri · 2013 · Seminars in Dialysis
47. Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial)
    Sadiya S. Khan, Umberto Campia, Ovidiu Chioncel, Faiez M. Zannad, Patrick Rossignol, Aldo Pietro Maggioni, Karl B Swedberg, Marvin A. Konstam, Michele Senni, Savina Nodari et al. · 2015 · The American Journal of Cardiology
48. Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: An ancillary study of the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE)
    A. Bavry, E. Handberg, T. Huo, A. Lerman, A. Quyyumi, C. Shufelt, Barry L. Sharaf, C. Merz, R. Cooper-DeHoff, G. Sopko et al. · 2014 · American Heart Journal
49. Novel interactions of the mineralocorticoid receptor
    Peter J. Fuller · 2015 · Molecular and Cellular Endocrinology
50. Aldosterone Antagonists and Outcomes in Real-World Older Patients With Heart Failure and Preserved Ejection Fraction
    Kanan Patel, Gregg C. Fonarow, Dalane W. Kitzman, Inmaculada Aban, Thomas E. Love, Richard M. Allman, Mihai Gheorghiade, Ali Ahmed · 2013 · JACC Heart Failure
51. From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress
    Constantijn Franssen, H. Sophia Chen, Nazha Hamdani, Walter J. Paulus · 2015 · Heart
52. Estrogen Signaling in the Adrenal Cortex
    Brasilina Caroccia, Teresa Maria Seccia, Matthias Barton, Gian Paolo Rossi · 2016 · Hypertension
53. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials
    Georg Wolff, Yingfeng Lin, Athanasios Karathanos, Maximilian Brockmeyer, Susanne Wolters, Bernd Nowak, Alexander Fürnkranz, Hisaki Makimoto, Malte Kelm, Volker T. Schulze · 2017 · Clinical Research in Cardiology
54. Intestinal Mineralocorticoid Receptor Contributes to Epithelial Sodium Channel–Mediated Intestinal Sodium Absorption and Blood Pressure Regulation
    Toshifumi Nakamura, Isao Kurihara, Sakiko Kobayashi, Kenichi Yokota, Ayano Murai‐Takeda, Yuko Mitsuishi, Mitsuha Morisaki, Nao Kohata, Yosuke Oshima, Yukiko Minami et al. · 2018 · Journal of the American Heart Association
55. One-Year Outcomes of Acute Decompensated Systolic Heart Failure in Taiwan: Lessons from TSOC-HFrEF Registry.
    Hung Yu Chang, Chun Chieh Wang, Yen‐Wen Wu, Pao Hsien Chu, Chih‐Cheng Wu, Chih‐Hsin Hsu, Ming-Shien Wen, Wen‐Chol Voon, Wei Shiang Lin, Jin Long Huang et al. · 2017 · PubMed Central
56. Targeting Ca2 + Handling Proteins for the Treatment of Heart Failure and Arrhythmias
    Alexandra Njegić, Claire Wilson, Elizabeth J. Cartwright · 2020 · Frontiers in Physiology
57. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone
    Hiromi Rakugi, Satoru Yamakawa, Kotaro Sugimoto · 2020 · Hypertension Research
58. Sex-related differences in the pharmacological treatment of heart failure
    Juan Luis Tamargo, Ricardo Caballero, Eva Delpón · 2021 · Pharmacology & Therapeutics
59. Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines
    Hiroyuki Tsutsui · 2022 · Pharmacology & Therapeutics
60. The double burden: type 1 diabetes and heart failure—a comprehensive review
    María Teresa Julián, Alejandra Pérez-Montes de, Josep Julve, Núria Alonso · 2024 · Cardiovascular Diabetology
61. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta‐analysis
    Lijun Hu, Yunqing Chen, Songbai Deng, Jianlin Du, Qiang She · 2012 · British Journal of Clinical Pharmacology
62. Converging Indications of Aldosterone Antagonists (Spironolactone and Eplerenone): A Narrative Review of Safety Profiles
    Mohammed Ibn-Mas’ud Danjuma, Ipshita Mukherjee, Janine Makaronidis, Serge Osula · 2014 · Current Hypertension Reports
63. Low-Dose Spironolactone Prevents Apoptosis Repressor With Caspase Recruitment Domain Degradation During Myocardial Infarction
    T. Y. L. Le, Mahidi Mardini, V. Howell, J. Funder, A. Ashton, A. Mihailidou · 2012 · HYPERTENSION
64. Association of Smoking, Sleep Apnea, and Plasma Alkalosis With Nocturnal Ventricular Arrhythmias in Men With Systolic Heart Failure
    Shahrokh Javaheri, Rakesh Shukla, LAURA F. WEXLER · 2011 · CHEST Journal
65. Mechanosignaling in the vasculature: emerging concepts in sensing, transduction and physiological responses
    Shampa Chatterjee, Keigi Fujiwara, Néstor Gustavo Pérez, Masuko Ushio‐Fukai, Aron B. Fisher · 2015 · American Journal of Physiology-Heart and Circulatory Physiology
66. De Novo Acute Heart Failure and Acutely Decompensated Chronic Heart Failure
    Astrid Hummel, Klaus Empen, Marcus Dörr, Stephan Burkhard Felix · 2015 · Deutsches Ärzteblatt international
67. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice
    Benjamin Bonnard, Marie Pieronne-Deperrois, Zoubir Djerada, Soumaya El Moghrabi, Peter Kolkhof, Antoine Ouvrard‐Pascaud, Paul G.H. Mulder, Frédéric Jaisser, Smail Messaoudi · 2018 · Journal of Molecular and Cellular Cardiology
68. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality
    Joost C. Beusekamp, Jasper Tromp, John G.F. Cleland, Michael M. Givertz, Marco Metra, Christopher M. O’Connor, John R. Teerlink, Piotr P. Ponikowski, Wouter Ouwerkerk, Dirk Jan van Veldhuisen et al. · 2019 · JACC Heart Failure
69. Myocardial Effects of Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction
    Adam Kenneth McDiarmid, Peter Swoboda, Bara Erhayiem, Katrina Bounford, Petra Bijsterveld, Keith Tyndall, Graham J. Fent, Pankaj Garg, Laura Elizabeth Dobson, Tarique A Musa et al. · 2019 · Journal of the American Heart Association
70. Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial
    Masanori Asakura, Shin Ito, Takahisa Yamada, Yoshihiko Saito, Kazuo Kimura, Akira Yamashina, Atsushi Hirayama, Youichi Kobayashi, Akihisa Hanatani, Mitsuru Tsujimoto et al. · 2020 · European Heart Journal - Cardiovascular Pharmacotherapy
71. The signaling pathway for aldosterone-induced mitochondrial production of superoxide anion in the myocardium
    Mariela B. Nolly, Claudia I. Caldiz, Alejandra M. Yeves, María Celeste Villa‐Abrille, Patricio E. Morgan, Nicolas Amado Mondaca, Enrique Leo Portiansky, Gladys E. Chiappe de Cingolani, Horacio Eugenio Cingolani, Irene L. Ennis · 2013 · Journal of Molecular and Cellular Cardiology
72. Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure
    Orly Vardeny, Larisa H. Cavallari, Brian Lee Claggett, Akshay Suvas Desai, Inder S. Anand, Patrick Rossignol, Faiez M. Zannad, Bertram Pitt, Scott David Solomon · 2013 · Circulation Heart Failure
73. Relationship Between Galectin-3 Levels and Mineralocorticoid Receptor Antagonist Use in Heart Failure: Analysis From HF-ACTION
    Mona Fiuzat, Phillip J. Schulte, Gary Michael Felker, Tariq Ahmad, Megan Lee Neely, Kirkwood F. Adams, Mark Donahue, William E. Kraus, Ileana L. Piña, David J. Whellan et al. · 2013 · Journal of Cardiac Failure
74. Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management
    Hung‐Yu Chang, Kuan-Chun Chen, Man-Cai Fong, An-Ning Feng, Hao‐Neng Fu, Kuan‐Chih Huang, Eric Y. Chong, Wei‐Hsian Yin · 2019 · Journal of Cardiology
75. Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study
    Marie Bretagne, Bénédicte Lebrun‐Vignes, Antoine Pariente, Christian M. Shaffer, Gabriel G. Malouf, Pauline Dureau, Camille Potey, Christian Funck‐Brentano, Dan M. Roden, Javid J. Moslehi et al. · 2019 · Archives of cardiovascular diseases
76. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
    Daiji Kawanami, Yuichi Takashi, Yoshimi Muta, Naoki Oda, Dai Nagata, Hiroyuki Takahashi, Makito Tanabe · 2021 · Frontiers in Pharmacology
77. Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibition According to Left Ventricular Ejection Fraction in DAPA-HF
    Dewan, Pooja, Solomon, Scott D., Jhund, Pardeep S., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, DeMets, David L., Sabatine, Marc S. et al. · 2020 · European Journal of Heart Failure
78. Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST
    Christian W. Hamm, Jean‐Pierre Bassand, Stefan Agewall, Jeroen Joost Bax, Eric H. Boersma, Héctor Bueno, Pio Caso, Dariusz Dudek, Stephan Gielen, Kurt Huber et al. · 2012 · Revista Española de Cardiología
79. Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial
    Michael W. Walsh, David Collister, Martin Gallagher, Patrick Barry Mark, Janak de Zoysa, Jessica Tyrwhitt, Karthik Tennankore, Gilmar Reis, Denis Xavier, Wen J Liu et al. · 2025 · The Lancet
80. Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy
    Luis Miguel Ruilope, Rajiv Agarwal, Juliana C.N. Chan, Mark Emmanuel Cooper, Ron T. Gansevoort, Hermann G. Haller, Giuseppe Remuzzi, Peter R Rossing, Roland Erich Schmieder, Christina Nowack et al. · 2014 · American Journal of Nephrology
81. Management of heart failure
    Henry Krum, Andrea L Driscoll · 2013 · The Medical Journal of Australia
82. Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials
    Yanmei Chen, He Wang, Yongkang Lu, Xiaobo Huang, Yulin Liao, Jianping Bin · 2015 · BMC Medicine
83. Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy
    Henry Krum, Harry H. Shi, Bertram Pitt, John J.V. McMurray, Karl B Swedberg, Dirk Jan van Veldhuisen, John Vincent, Stuart Pocock, Faiez M. Zannad · 2013 · Circulation Heart Failure
84. Parathyroid Hormone, A Crucial Mediator of Pathologic Cardiac Remodeling in Aldosteronism
    Michael Rutledge, Victor Farah, Adedayo A. Adeboye, Michael R. Seawell, Syamal K. Bhattacharya, Karl T. Weber · 2012 · Cardiovascular Drugs and Therapy
85. The Mineralocorticoid Receptor in Salt-Sensitive Hypertension and Renal Injury
    Nobuhiro Ayuzawa, Toshiro Fujita · 2021 · Journal of the American Society of Nephrology
86. Pharmacological treatment of aldosterone excess
    Jaap Deinum, Niels Peter Riksen, Jacques W.M. Lenders · 2015 · Pharmacology & Therapeutics
87. Salt in Health and Disease — A Delicate Balance
    Theodore A. Kotchen, Allen W. Cowley, Edward D Frohlich · 2013 · New England Journal of Medicine
88. SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis
    Razuk, Victor, Chiarito, Mauro, Cao, Davide, Nicolas, Johny, Pivato, Carlo A, Camaj, Anton, Power, David, Beerkens, Frans, Jones, Davis, Alter, Aviv et al. · 2022 · European Heart Journal - Cardiovascular Pharmacotherapy
89. Cardioprotective strategies against doxorubicin-induced cardiotoxicity: A review from standard therapies to emerging mitochondrial transplantation
    Kanako Ito‐Hagiwara, Jun Hagiwara, Yusuke Endo, Lance B. Becker, Kei Hayashida · 2025 · Biomedicine & Pharmacotherapy
90. Effect of Eplerenone on Maintenance of Sinus Rhythm After Catheter Ablation in Patients With Long-Standing Persistent Atrial Fibrillation
    Yoko Ito, Hiro Yamasaki, Yoshihisa Naruse, Kentaro Yoshida, Takashi Kaneshiro, Nobuyuki Murakoshi, Miyako Igarashi, Kenji Kuroki, Takeshi Machino, Dongzhu Xu et al. · 2013 · The American Journal of Cardiology
91. Direct Role for Smooth Muscle Cell Mineralocorticoid Receptors in Vascular Remodeling: Novel Mechanisms and Clinical Implications
    Jenny B. Koenig, Iris Zamir Jaffe · 2014 · Current Hypertension Reports
92. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients
    Panayota G. Flevari, Sofia Kalogeropoulou, Athina Drakou, Dionyssios I. Leftheriotis, Fotis K. Panou, John P Lekakis, Demetrios Kremastinos, Demetrios Vlahakos · 2013 · Journal of Hypertension
93. Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial
    Nicolas Girerd, Timothy John Collier, Stuart Pocock, Henry Krum, John J.V. McMurray, Karl B Swedberg, Dirk Jan van Veldhuisen, John Vincent, Bertram Pitt, Faiez M. Zannad · 2015 · European Heart Journal
94. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects
    Roberto Vettor, Silvio E. Inzucchi, Paola Fioretto · 2017 · Diabetologia
95. Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis
    Giacomo Tini, Edoardo Bertero, Alessio Signori, Maria Pia Sormani, Christoph Maack, Rudolf A. de Boer, Marco Canepa, Pietro Ameri · 2020 · Journal of the American Heart Association
96. Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction
    Stephen John Greene, Xi Tan, Yu‐Chen Yeh, Mark J. Bernauer, Omer Zaidi, Mei Yang, Javed Butler · 2021 · Heart Failure Reviews
97. Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved
    Sarafidis, Pantelis, Papadopoulos, Christodoulos E., Kamperidis, Vasilios, Giannakoulas, George, Doumas, Michael · 2021 · Hypertension
98. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease
    Lerma, Edgar, White, William B., Bakris, George · 2023 · Postgraduate Medicine
99. Finerenone in diabetic kidney disease: A systematic review and critical appraisal
    Awadhesh Kumar Singh, Ritu Singh, Ritu Singh, Anoop Misra · 2022 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
100. Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment
     Marios Zisis, Maria Eleni Chondrogianni, Θεόδωρος Ανδρουτσάκος, Ilias Rantos, Evangelos K. Oikonomou, Antonios Chatzigeorgiou, Eva N. Kassi · 2025 · Biomolecules